Botox endorsed for migraine prevention in latest NICE decisions
Botulinum toxin type A has been endorsed for NHS use in England and Wales for the prevention of headaches in adults with chronic migraine.
In final guidance published today (27 June 2012), the National Institute for Health and Clinical Excellence has recommended Allergan’s for use in patients whose migraines have not responded to at least three prophylactic drug treatments and whose condition is appropriately managed to prevent medication overuse.
NICE also gave positive recommendations for the use of (Zytiga; Janssen) and (Tarceva; Roche), under patient access schemes.
Lapatinib (Tyverb; GlaxoSmithKline) and trastuzumab (Herceptin; Roche) were rejected for use, in combination with an aromatase inhibitor, for the treatment of post-menopausal women with metastatic, hormone-receptor-positive breast cancer.
Citation: Electronicjuice URI: 11103456
Recommended from Pharmaceutical Press
Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.£138.50
Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.£262.50